CytoLogic and the UNLEASH® Device
CytoLogic, Inc. was incorporated in 2003 to develop the immunotherapy device invented by Dr. Mark D. Howell at Colorado State University in Fort Collins. With support from the CSU Research Foundation, Dr. Howell’s discoveries led to the UNLEASH® technology, a powerful experimental tool that represents a new approach to treating cancerous tumors. The extracorporeal (outside the body) device effectively up-regulates (unleashes) a key immune system signaling molecule (cytokine) by removing its inhibitor proteins.
CytoLogic exists to further develop Dr. Howell’s medical device and to gain FDA approval for a wide-spectrum of cancer indications.
Board of Directors and Management
Larry M. David, Chief Executive Officer/Chairman of the Board
Larry invested in CytoLogic in 2006 and became a Director in 2007. He was elected Chairman of the Board of Directors in October, 2007 and Chief Executive Officer in 2011. Mr. David has been instrumental in maintaining the operations of the company, including debt management, intellectual property maintenance, licensing negotiations, and investor relations. Mr. David is an entrepreneur and civic leader experienced in small business development and non-governmental organizations. His background involves real estate, educational publishing, consulting, and leadership of NGO’s focused on international relations, acting as principal, owner, president/CEO, or chairman in more than a dozen enterprises.
Bernard L. Kasten, Jr. M.D., Chief Scientific Officer, Vice Chairman of the Board
Dr. Kasten is Acting CEO, President and Executive Chairman of the Board for GeneLink, Inc. He has been an investor and Director of CytoLogic since 2003 and Vice Chairman since 2007. Dr. Kasten is a Diplomat of the American Board of Pathology with Certification in Anatomic and Clinical Pathology with sub-specialty certification in Medical Microbiology. Dr. Kasten is an author of “Infectious Disease Handbook” 1st through 5th Editions 1994-2003 and the “Laboratory Test Handbook” 1st through 4th Editions 1984-1996 published by Lexi-Comp Inc., Hudson, Ohio. Dr. Kasten has been active with the College of American Pathologists (CAP) serving as Chairman of its Publication Committee from 1985-1993, its Management Resources Committee from 1993-1998 and Chairman of its Internet Editorial Board from 1999-2003. Dr. Kasten received the College of American Pathologists Presidents Medal Award for Outstanding Service in 1989 and the College of American Pathologists Frank W. Hartman Award in 1993 for Meritorious Service to the College (Founding CAP Today), the organization’s highly successful monthly tabloid magazine. Dr. Kasten’s professional staff appointments have included the Cleveland Clinic, Northeastern Ohio Universities College of Medicine, the Bethesda Hospitals and Quest Diagnostics. Dr. Kasten served eight years, 1996-2004, at Quest Diagnostics Incorporated [NYSE-DGX], where he was Chief Laboratory Officer; Vice-President of Business Development for Science and Medicine and Vice-President of Medical Affairs of a Quest Diagnostics wholly-owned subsidiary, MedPlus Inc. Dr. Kasten joined SIGA Technologies, Inc. [NASDAQ-SIGA] as a Board of Directors member in May 2003, and accepted the appointment as SIGA’s Chief Executive Officer in July of 2004, serving through April 2006. Dr. Kasten is Chairman of the Board of Cleveland Bio Labs Inc. [NASDAQ-CBLI], and also serves on the Board of Directors of Enzo Biochem, Inc. [ENZ-NYSE] privately-held CytoLogic Inc., and Riggs- Heinrich Media Inc. He is a graduate of Miami University, BA Chemistry, and the Ohio State University College of Medicine MD. His residency was served at the University of Miami, Florida and fellowships at the NIH Clinical Center and National Cancer Institute.
Randall J. Daughenbaugh, Ph.D., Director
Dr. Daughenbaugh was co-founder and President of Hauser, Inc. which grew to $60M in annual sales and became publicly traded on NASDAQ. Hauser won contracts from the National Cancer Institute to isolate anti-tumor compounds from natural sources. One of the compounds isolated by Hauser was paclitaxel, from the bark of the yew tree. This chemotherapy product is commonly known as Taxol, an agent used for certain types of ovarian and breast cancers. It works by attacking the cancer cell division process and was the first in its class. He consults in the area of process chemistry, holds numerous patents and has published multiple works in chemistry and related fields. Dr. Daughenbaugh received his Ph.D. in Chemistry from the University of Colorado.
Patricia J. Wheeler, Chief Financial Officer
Ms. Wheeler has more than 30 years experience in the medical device and pharmaceutical industries. She spent 21 years at COBE Laboratories, a global leader in medical devices for extracorporeal applications, including apheresis products. At COBE, she served 10 years in corporate accounting and 11 years on the Management Team of the Cardiovascular Division. Ms. Wheeler graduated Cum Laude from Regis University in Denver, CO, with a degree in Business. She has been a member of Financial Executives International since 1996.
David B. Goffredo, Strategic Advisor
Mr. Goffredo is the former president of Abbott Laboratories Pharmaceutical Products Division. During his nearly 20 years at Abbott, he held several management positions in the company’s pharmaceutical business including Vice President, European Operations. Prior to Abbott Labs, Mr. Goffredo spent 11 years with E.R. Squibb & Sons, Inc. David holds a bachelor’s degree in Business Administration from Rowan College and a Master’s Degree in Management from Northwestern University’s Kellogg Graduate School of Management.
Charles M. Leir, Ph.D., Chairman, Scientific Advisory Board, Corporate Scientist, 3M (Retired)
Dr. Charles M. Leir retired from 3M after 37 years of service as one of 16 Corporate Scientists. He is a consultant for Zinpro Corporation, a producer of micro-nutrients for animal nutrition. In 1993, he was the winner of the Carlton Award, 3M’s highest honor for technical achievement. Dr. Leir has worked in process research & development of drug molecules; organic chemistry of biologically active molecules; polymers for adhesives and films; and silicone polymers. He has over 60 patents. Notably, he worked on attachment chemistry for anchoring biological molecules to porous bead surfaces, the technology CytoLogic uses to bind M4 to resin beads, creating the matrix used in the UNLEASH® column. Dr. Leir was a chemist with Pfizer from 1967 to 1970. He received his BS in Chemistry from University of Iowa in 1963 and his MS/PhD from the University of Illinois in 1967. He became a Cytologic investor in 2005.